 HOUSTON, Jan. 7, 2022 PRNewswire -- Moleculin Biotech, Inc. , Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022. 